Alzheimer’s disease (AD) affects an estimated 24 million people worldwide. Although several medications have been FDA approved for the treatment of AD, there is still an urgent need for new therapies because like other forms of dementia, AD is complex and difficult to treat with one drug or intervention.
We know how important innovative, translatable animal models are to research that focuses on accelerating the identification of new drug targets and developing new therapies for diseases like AD. In this webinar, we will introduce you to our novel AD mouse models, specifically our FAD4T mice and our Next-Generation AD models. We will also describe other exciting models available for researching various neurodegenerative diseases. |
|
|
|
| Guest Speaker
Hao Qi, PhD
R&D Scientist |
|
|
|
| Guest Speaker
Steve Smith, PhD
Business Development Director |
|
|
|
1st Broadcast: KST 20:00, CET 12:00, March 29th, 2022 |
|
| |
|
2nd Broadcast: EST 15:00, PST 12:00, March 29th, 2022 |
|
| |
|
ABOUT US
GemPharmatech is a leading provider of genetically engineered mouse models (GEMMs) and preclinical services to global R&D communities.
Tell: +1(617) 830-3212
Email: global...@gempharmatech.com
Address: 1521 Concord Pike, Suite 301, Wilmington, DE 19803, USA |
|
| |
|
© Copyright 2022 GemPharmatech. All Rights Reserved. |
|
|
|
|